Successful Placement: IGM Biosciences

IGM Biosciences Appoints Daniel S. Chen, M.D., Ph.D., as Chief Medical Officer

MOUNTAIN VIEW, Calif., Aug. 1, 2018 – IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointments of Daniel S. Chen, M.D., Ph.D., to the newly created position of Chief Medical Officer.

Dr. Chen will be responsible for global clinical development of IGM’s emerging pipeline of proprietary IgM antibodies. He joins IGM with more than 20 years of experience in cancer immunotherapy research and development, most recently as Vice President, Global Head of Cancer Immunotherapy Development at Genentech/Roche. Read the full release